Once again, World Diabetes Day, celebrated on Nov. 14 every year, has come around, highlighting new initiatives in the diabetes tech space. The date marks the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922. It also lands during the American Diabetes Association’s National Diabetes Awareness Month. […]
Medtronic
The top CGM stories of 2025
Millions of people worldwide are looking for ways to manage their diabetes. That’s where the continuous glucose monitor (CGM) comes in. The CGM market is expected to experience substantial, double-digit percentage growth over the next five years, reaching nearly $29 billion by 2030. Market leaders Abbott and Dexcom continue to establish their hold on the […]
Billie Jean King supports Medtronic Diabetes awareness initiative
The annual Medtronic (NYSE:MDT) diabetes awareness initiative this year has the backing of sporting legend Billie Jean King. King, a former world No. 1 tennis player and pioneer in women’s sports, is participating in the company’s Blue Balloon Challenge this year. Introduced in 2021, the movement encourages people with diabetes to help drive awareness and […]
12 things you need to know about the CGM market
The CGM market is an exciting, fast-growing, multibillion-dollar sector for the medical device industry, according to our latest Medtech Market Intelligence Report for MassDevice. The report on the CGM market — available for purchase on MassDevice — draws on numerous sources, including but not limited to: medical associations, government data, medical journals, leading medtech publications, clinical […]
CGM market report: Significant growth is ahead
As millions of people worldwide seek ways to manage their diabetes, the continuous glucose monitor (CGM) market continues to grow rapidly. Medtech market analysts project significant growth for the market over the next five years. Chrystal Larsen, a veteran medtech market analyst, produced a detailed report for MassDevice outlining the future of the CGM market. The report covers […]
Court sides with Medtronic in insulin pump class action suit
A Minnesota judge has dismissed a class action lawsuit alleging securities fraud related to insulin pumps made by Medtronic (NYSE:MDT). Laura M. Provinzino, U.S. District Judge for the District of Minnesota, granted Medtronic’s motion to dismiss the suit initially brought forward by investors in 2022. Provinzino’s dismissal comes about a year-and-a-half after Katherine M. Menendez, […]
Medtronic begins rollout of MiniMed 780G with Instinct sensor made by Abbott
Medtronic (NYSE:MDT) announced that its Instinct sensor, made by Abbott, is now available to order with the MiniMed 780G pump. The medtech giant’s diabetes unit — one of the largest diabetes tech businesses in the world — earlier this month picked up FDA clearance for its SmartGuard algorithm as an interoperable automated glycemic controller (iAGC). […]
Medtronic reports positive 3-year automated insulin delivery data
Medtronic (NYSE:MDT) today shared three-year real-world evidence highlighting improvements with its MiniMed 780G automated insulin delivery system. MiniMed 780G, the company’s latest-generation AID system, offers meal detection technology and provides automatic adjustments and corrections to sugar levels every five minutes. This occurs for both basal (background) and bolus (mealtime) insulin needs. Data demonstrated rapid, sustained […]
Medtronic gets FDA nods for MiniMed 780G with Abbott Instinct sensor, expansion to type 2
Medtronic (NYSE:MDT) announced today that the FDA granted two major approvals to broaden access to its MiniMed 780G system. First, the FDA granted clearance for its SmartGuard algorithm as an interoperable automated glycemic controller (iAGC). This enables integration with a sensor made by Abbott, designed specifically through a collaboration between the medtech giants. Second, the […]
Medtronic says MiniMed separation remains on track, next-gen pump submissions on the way
Medtronic (NYSE:MDT) officials today said that the company’s planned separation of its Diabetes business is on the right track. The medtech giant announced in May that it planned to separate the Diabetes unit into a standalone, publicly traded company. The move sought to create “a more focused Medtronic” with a more simplified portfolio in high-margin growth markets. […]
